Foresight Group Ltd Liability Partnership Increases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Foresight Group Ltd Liability Partnership raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 159.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,216 shares of the medical research company’s stock after purchasing an additional 747 shares during the period. Foresight Group Ltd Liability Partnership’s holdings in Thermo Fisher Scientific were worth $752,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CFM Wealth Partners LLC purchased a new stake in Thermo Fisher Scientific in the first quarter valued at $216,000. Elevated Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 6.2% in the first quarter. Elevated Capital Advisors LLC now owns 1,372 shares of the medical research company’s stock valued at $797,000 after acquiring an additional 80 shares during the last quarter. Brookstone Capital Management increased its stake in Thermo Fisher Scientific by 252.4% in the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after purchasing an additional 3,142 shares during the period. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 14.6% in the first quarter. Revolve Wealth Partners LLC now owns 433 shares of the medical research company’s stock valued at $251,000 after purchasing an additional 55 shares during the period. Finally, Wealthcare Advisory Partners LLC increased its stake in Thermo Fisher Scientific by 359.0% in the first quarter. Wealthcare Advisory Partners LLC now owns 5,334 shares of the medical research company’s stock valued at $3,100,000 after purchasing an additional 4,172 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TMO. Bernstein Bank boosted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday. Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Barclays upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $620.00 and gave the company an “equal weight” rating in a research note on Tuesday, October 15th. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Finally, Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $656.00.

Thermo Fisher Scientific Trading Down 1.5 %

Shares of NYSE:TMO opened at $586.25 on Wednesday. The company’s 50-day moving average price is $607.55 and its 200 day moving average price is $584.45. The company has a market cap of $223.95 billion, a PE ratio of 36.37, a P/E/G ratio of 3.85 and a beta of 0.77. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.15 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at $1,108,408.42. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock valued at $14,094,292 in the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.